DBV Technologies S.A. (LON:0QAJ)

Market Cap	956.48M +1,173.8%
Revenue (ttm)	4.09M -56.0%
Net Income	-93.09M
EPS	-0.79
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,377
Average Volume	12,449
Open	4.025
Previous Close	4.095
Day's Range	3.705 - 4.060
52-Week Range	0.674 - 4.460
Beta	-0.19
RSI	51.86
Earnings Date	Mar 5, 2026

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company’s product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2002
• Employees: 117
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0QAJ

Financial Performance

In 2024, DBV Technologies's revenue was $4.15 million, a decrease of -73.61% compared to the previous year's $15.73 million. Losses were -$113.92 million, 56.6% more than in 2023.

Financial numbers in USD